These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1632391)

  • 21. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.
    Tardif JC; Côté G; Lespérance J; Gosselin G; Joyal M; de Guise P; Bilodeau L; Doucet S; Harel F; Couturier A; Gallo R; Grégoire J
    Can J Cardiol; 2001 Jan; 17(1):49-55. PubMed ID: 11173314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial).
    Boccuzzi SJ; Weintraub WS; Kosinski AS; Roehm JB; Klein JL
    Am J Cardiol; 1998 Mar; 81(5):632-6. PubMed ID: 9514463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.
    Foley DP; Serruys PW
    Br J Clin Pract Suppl; 1996 Jan; 77A():40-53. PubMed ID: 8729590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.
    Foley DP; Serruys PW
    Br J Clin Pract Suppl; 1994 Dec; (77):39-50. PubMed ID: 19496272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA?
    Kanemitsu S; Takekoshi N; Matsui S; Tsugawa H; Ohkubo S; Kitayama M; Matsuda T; Senma J; Masuyama K; Yamagata T; Murakami E
    Ther Apher; 1998 Feb; 2(1):65-70. PubMed ID: 10227791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II).
    Savage MP; Goldberg S; Bove AA; Deutsch E; Vetrovec G; Macdonald RG; Bass T; Margolis JR; Whitworth HB; Taussig A
    Circulation; 1995 Dec; 92(11):3194-200. PubMed ID: 7586303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
    Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
    Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EPA in the prevention of restenosis post PTCA.
    Bowles MH; Klonis D; Plavac TG; Gonzales B; Francisco DA; Roberts RW; Boxberger GR; Poliner LR; Galichia JP
    Angiology; 1991 Mar; 42(3):187-94. PubMed ID: 2018239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART).
    Yamaguchi H; Lee YJ; Daida H; Yokoi H; Miyano H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F
    Chem Phys Lipids; 1994 Jan; 67-68():399-403. PubMed ID: 8187240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.
    Onaka H; Hirota Y; Kita Y; Tsuji R; Ishii K; Ishimura T; Kawamura K
    Jpn Circ J; 1994 Feb; 58(2):100-6. PubMed ID: 8196151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group.
    Daida H; Lee YJ; Yokoi H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F; Kato H; Kutsumi Y
    Am J Cardiol; 1994 Jun; 73(15):1037-40. PubMed ID: 8198026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
    Desmet W; Vrolix M; De Scheerder I; Van Lierde J; Willems JL; Piessens J
    Circulation; 1994 Jan; 89(1):385-92. PubMed ID: 8281674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transoesophageal pacing echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty.
    Hoffmann R; Kleinhans E; Lambertz H; Flachskampf FA; Uebis R; Buell U; Hanrath P
    Eur Heart J; 1994 Jun; 15(6):823-31. PubMed ID: 8088272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of high dose verapamil on restenosis after peripheral angioplasty.
    Schweizer J; Kirch W; Koch R; Hellner G; Uhlmann K
    J Am Coll Cardiol; 1998 May; 31(6):1299-305. PubMed ID: 9581724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.
    Cairns JA; Gill J; Morton B; Roberts R; Gent M; Hirsh J; Holder D; Finnie K; Marquis JF; Naqvi S; Cohen E
    Circulation; 1996 Oct; 94(7):1553-60. PubMed ID: 8840843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restenosis after successful percutaneous transluminal coronary angioplasty: the Montreal Heart Institute experience.
    Guiteras Val P; Bourassa MG; David PR; Bonan R; Crépeau J; Dyrda I; Lespérance J
    Am J Cardiol; 1987 Jul; 60(3):50B-55B. PubMed ID: 2956844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ischemia: reperfusion injury and restenosis after coronary angioplasty.
    Park JW; Braun P; Mertens S; Heinrich KW
    Ann N Y Acad Sci; 1992 Sep; 669():215-36. PubMed ID: 1444028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial.
    Johansen O; Brekke M; Seljeflot I; Abdelnoor M; Arnesen H
    J Am Coll Cardiol; 1999 May; 33(6):1619-26. PubMed ID: 10334433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test.
    Bengtson JR; Mark DB; Honan MB; Rendall DS; Hinohara T; Stack RS; Hlatky MA; Califf RM; Lee KL; Pryor DB
    Am J Cardiol; 1990 Jan; 65(1):28-34. PubMed ID: 2294678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.